OpenLB
Open Library of Bioscience
Advanced Search
Anticancer research
10, 2016;36 (10): 5307-5314.

Plasma Adiponectin and Hepatocellular Carcinoma Survival Among Patients Without Liver Transplantation.

Jing Shen, Chih-Ching Yeh, Qiao Wang, Irina Gurvich, Abby B Siegel, Regina M Santella
Author Information
  1. Jing Shen: Departments of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, U.S.A. js2182@cumc.columbia.edu.
  2. Chih-Ching Yeh: Departments of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, U.S.A.
  3. Qiao Wang: Departments of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, U.S.A.
  4. Irina Gurvich: Departments of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, U.S.A.
  5. Abby B Siegel: Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, U.S.A.
  6. Regina M Santella: Departments of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, U.S.A.
PMID: 27798893 DOI: 10.21873/anticanres.11103

Abstract

AIM: To investigate the levels of leptin and adiponectin in prediction of hepatocellular carcinoma (HCC) survival among patients without liver transplantation.
MATERIALS AND METHODS: We measured pretreatment plasma leptin and adiponectin in 172 HCC cases who were prospectively followed-up over 7 years.
RESULTS: Gender, hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, high body mass index (BMI), diabetes mellitus (DM) history and Child-Pugh (CP) class were associated with leptin and adiponectin levels, while α-fetoprotein (AFP) and presence of metastasis, being outside the Milan criteria and Barcelona clinic liver cancer (BCLC) stage, were significantly associated with liver transplantation and HCC survival. No significant association was observed for leptin or adiponectin and HCC survival in the overall group. In subgroup analyses among those without liver transplantation, we found significant associations between metastasis, Milan criteria, BCLC stage, hepatitis B surface antigen (HBsAg) and HCC survival. When separately determining the Cox proportional hazard models and Kaplan-Meier survival curves by liver transplantation status, higher adiponectin was significantly associated with an increased hazard ratio (HR) of death of 1.72 (95% confidence interval (CI)=1.12-2.64), i.e. poor survival among patients without liver transplantation. A multivariate Cox proportional hazard model, including adiponectin, CP class, presence of metastasis, tumor outside of Milan criteria, AFP and BCLC stage B/C parameters, also showed significant association with poor HCC survival (likelihood ratio test p<0.0001). No significant impact was observed for leptin on HCC survival regardless of liver transplantation status.
CONCLUSION: Higher levels of plasma adiponectin may predict poor HCC survival among patients without liver transplantation.

Keywords

Adiponectin HCC leptin liver transplantation survival

References

  1. Hepatology. 2015 Jan;61(1):191-9 [PMID: 25142309]
  2. Hepatology. 2011 Mar;53(3):1020-2 [PMID: 21374666]
  3. Annu Rev Pathol. 2016 May 23;11:421-49 [PMID: 27193454]
  4. Biol Pharm Bull. 2015;38(7):961-5 [PMID: 26133703]
  5. PLoS One. 2013 Aug 22;8(8):e73183 [PMID: 23991180]
  6. Surg Today. 2017 Feb;47(2):151-158 [PMID: 27061803]
  7. Hepatology. 2014 Sep;60(3):858-71 [PMID: 24443059]
  8. J Surg Oncol. 2012 Aug 1;106(2):181-7 [PMID: 22287480]
  9. Biochem Pharmacol. 2015 Jan 15;93(2):221-31 [PMID: 25514170]
  10. J Clin Pathol. 2006 Sep;59(9):930-4 [PMID: 16565221]
  11. Surg Oncol Clin N Am. 2015 Jan;24(1):1-17 [PMID: 25444466]
  12. Endocr Rev. 2012 Aug;33(4):547-94 [PMID: 22547160]
  13. J Gastroenterol. 2014 Sep;49(9):1342-51 [PMID: 24132578]
  14. Am J Epidemiol. 2015 Aug 1;182(3):187-97 [PMID: 26085045]
  15. Nature. 1998 Oct 22;395(6704):763-70 [PMID: 9796811]
  16. Pathol Oncol Res. 2014 Jul;20(3):667-75 [PMID: 24619866]
  17. Cancer Epidemiol Biomarkers Prev. 2013 Jul;22(7):1319-24 [PMID: 23651666]
  18. Int J Epidemiol. 2014 Aug;43(4):1226-36 [PMID: 24737805]
  19. Eur J Cancer Prev. 2014 May;23(3):158-65 [PMID: 23929213]
  20. Eur J Epidemiol. 2014 Apr;29(4):261-75 [PMID: 24791703]
  21. J Intern Med. 2005 Sep;258(3):274-80 [PMID: 16115302]
  22. Hepatol Int. 2009 Jun;3(2):364-70 [PMID: 19669362]
  23. Oncology. 2015;88(1):57-68 [PMID: 25300295]
  24. N Engl J Med. 2011 Sep 22;365(12):1118-27 [PMID: 21992124]
  25. Tumour Biol. 2015 Apr;36(4):2983-92 [PMID: 25492487]
  26. Cancer Biol Med. 2016 Mar;13(1):101-19 [PMID: 27144066]

Grants

  1. P30 CA013696/NCI NIH HHS
  2. P30 ES009089/NIEHS NIH HHS
  3. R01 ES005116/NIEHS NIH HHS
  4. R03 CA156629/NCI NIH HHS

MeSH Term

Adiponectin
Carcinoma, Hepatocellular
Female
Hepatitis B
Hepatitis C
Humans
Leptin
Liver Neoplasms
Liver Transplantation
Male
Middle Aged
Neoplasm Staging
Proportional Hazards Models
alpha-Fetoproteins

Chemicals

ADIPOQ protein, human
AFP protein, human
Adiponectin
Leptin
alpha-Fetoproteins
Journal Article

Word Cloud

Created with Highcharts 10.0.0survivalHCClivertransplantationadiponectinleptinamongwithoutsignificantlevelspatientshepatitisassociatedmetastasisMilancriteriaBCLCstagehazardpoorplasmaBvirusCPclassAFPpresenceoutsidesignificantlyassociationobservedCoxproportionalstatusratioAdiponectinAIM:investigatepredictionhepatocellularcarcinomaMATERIALSANDMETHODS:measuredpretreatment172casesprospectivelyfollowed-up7yearsRESULTS:GenderHBVCHCVinfectionhighbodymassindexBMIdiabetesmellitusDMhistoryChild-Pughα-fetoproteinBarcelonacliniccanceroverallgroupsubgroupanalysesfoundassociationssurfaceantigenHBsAgseparatelydeterminingmodelsKaplan-MeiercurveshigherincreasedHRdeath17295%confidenceintervalCI=112-264iemultivariatemodelincludingtumorB/Cparametersalsoshowedlikelihoodtestp<00001impactregardlessCONCLUSION:HighermaypredictPlasmaHepatocellularCarcinomaSurvivalAmongPatientsWithoutLiverTransplantation

Similar Articles

Cited By